Table 4.
Median change (range) in Scr (mg/dL) and EGFR (mL/min/1.73m2) from baseline grouped by initial TDF regimen.
| Time (mo) | Atripla (n = 39) | Complera (n = 27) | Stribild (n = 31) | TDF + Background Therapy (n = 4) | Truvada + Background Therapy (n = 41) | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| ∆ Scr | ∆ eGFR | ∆ Scr | ∆ eGFR | ∆ Scr | ∆ eGFR | ∆ Scr | ∆ eGFR | ∆ Scr | ∆ eGFR | |
| 6 ± 1 | 0 (−0.4–0.3) |
0 (−47–23) |
0 (−0.5–0.1) |
0 (−13–36) |
0 (−0.3–0.3) |
0 (−37–35) |
0 (−0.1–0.3) |
0 (−14–6) |
−0.05 (−0.5–0.2) |
4 (−28–46) |
| 9 ± 1 | 0 (−0.5–0.5) |
0 (−67–27) |
0 (−0.5–0.3) |
0 (−24–45) |
0 (−0.5–0.1) |
0 (−12–23) |
−0.1 (−0.3–0.1) |
8.5 (−6–23) |
0 (−0.7–0.7) |
0 (−36–41) |
| 12 ± 1 | 0.1 (−0.7–0.5) |
−10 (−67–35) |
0.1 (−0.3–0.5) |
−4 (−51–36) |
0 (−0.4–0.4) |
0 (−29–20) |
0 (−0.2–0.6) | 0 (−23–14) |
0 (−0.5–0.4) |
0 (−37–20) |
| 18 ± 1 | 0.1 (−0.7–0.5) |
−9 (−59–35) |
0 (−0.3–0.3) |
0 (−30–36) |
0 (−0.4–0.3) |
−1 (−16–17) |
0.1 (0–0.2) |
−10 (−17–0) |
−0.05 (−1.3–0.2) |
4 (−23–26) |
| 24 ± 1 | 0.1 (−0.6–0.6) |
−14 (−59–27) |
0 (−0.3–0.3) |
−1 (−30–30) |
0 (−0.5–0.3) |
−3.5 (−24–20) |
0 (−0.1–0.3) |
−0.5 (−14–6) |
0 (−0.7–0.5) |
−1 (−38–56) |
| 36 ± 1 | 0.1 (−0.5–0.5) |
−10 (−60–20) |
0.1 (−0.2–0.3) |
−8 (−20–17) |
0 (−0.2–0.4) |
−1 (−23–20) |
0.1 (0.1–0.1) |
−6 (−6–−6) |
0 (−0.7–0.4) |
−1 (−41–20) |
| 44 | 0.2 (−0.6–0.5) |
−11 (−60–26) |
0.1 (−0.4–0.7) |
−8 (−37–54) |
0 (−0.5–0.3) |
−1 (−23–23) |
0.15 (0–0.2) |
−11 (−17–−1) |
0 (−0.5–0.6) |
−1 (−47–45) |